1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Bionime Corporation

Bionime Corporation

4737.TW
Bionime CorporationTW flagTaiwan Stock Exchange
56.90
TWD
+0.20
- -
4.40BMarket Cap

Total Valuation

Bionime Corporation carries a market capitalization of 4.40B, placing it among publicly traded companies globally. Its enterprise value stands at 6.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.40B
Enterprise Value6.59B

Share Statistics

Bionime Corporation currently has 67.93M shares outstanding.

Shares Outstanding67.93M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 2.18, and the price-to-book ratio stands at 7.92.

PE RatioN/A
PS Ratio2.18
PB Ratio7.92
P/TBV Ratio4.79
P/FCF Ratio5.12
P/OCF Ratio8.10

Enterprise Valuation

EV / Sales3.58
EV / EBITDAN/A
EV / EBITN/A
EV / FCF7.94

Financial Position

Bionime Corporation maintains a current ratio of 0.75, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 174.28, indicating elevated leverage, while an interest coverage ratio of -3.13 demonstrates limited ability to service its debt obligations.

Current Ratio0.75
Quick Ratio0.23
Debt / Equity174.28
Debt / EBITDA-15.05
Interest Coverage-3.13

Financial Efficiency

Return on Equity (ROE)-31.87
Return on Assets (ROA)-3.14
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.36

Taxes

Income Tax-70.08M
Effective Tax RateN/A

Stock Price Statistics

Bionime Corporation's stock has declined approximately -16.72765% over the past 52 weeks. The 50-day moving average sits at 57.42, while the 200-day moving average is 59.47.

Beta (5Y)N/A
52-Week Price Change-16.72765%
50-Day Moving Average57.42
200-Day Moving Average59.47
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Bionime Corporation generated 1.84B in revenue and converted that into -180.28M in net income, yielding earnings per share of -2.64. EBITDA reached -203.24M, while operating income came in at -203.24M.

Revenue1.84B
Gross Profit627.81M
Operating Income-203.24M
Pretax Income-249.40M
Net Income-180.28M
EBITDA-203.24M
EBIT-203.24M
Earnings Per Share (EPS)-2.64

Balance Sheet

Bionime Corporation holds 485.01M in cash and equivalents against 3.06B in total debt, resulting in a net debt position of 2.63B. Total book value stands at 506.11M, with working capital of -517.19M providing operational flexibility.

Cash & Cash Equivalents485.01M
Total Debt3.06B
Net Debt2.63B
Equity (Book Value)506.11M
Book Value Per Share7.44
Working Capital-517.19M

Cash Flow

Bionime Corporation produced 494.80M in operating cash flow over the past twelve months. After subtracting -288.39M in capital expenditures, free cash flow totaled 206.41M - equivalent to 3.04 per share.

Operating Cash Flow494.80M
Capital Expenditures-288.39M
Free Cash Flow206.41M
FCF Per Share3.04

Margins

Bionime Corporation operates with a gross margin of 34.15, reflecting its pricing power and cost economics. The operating margin of -11.05 and net profit margin of -9.81 provide insight into operational efficiency.

Gross Margin34.15
Operating Margin-11.05
Pretax Margin-13.57
Profit Margin-9.81
EBITDA Margin-11.05

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield2.71
FCF Yield19.55

Stock Splits

Bionime Corporation's most recent stock split took place on September 8, 2025 with a 1000:1099 split ratio.

Last Split Date9/8/2025
Split Ratio1000:1099

Scores

Bionime Corporation posts an Altman Z-Score of 0.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.67